Eduardo Martinez, MD
Urogynecology and Reconstructive Pelvic Surgery · Miami, FLNPI 1891957940
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (44.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Boston Scientific at 32.7% of the total. Reporting peaked in 2023 at $2,117 and has fallen 92.3% since, to $163 in 2025.
Across 125 payments — averaging $59.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Intuitive Surgical$2K
- Axonics, Inc.$1K
- AbbVie$323
- Sumitomo Pharma America, Inc.$195
- Femselect Inc.$106
- plus $799 from 22 others
What the payments were for
- Travel & lodging$3,30845%
- Food & beverage$2,61335%
- Education$1,50020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 14 | $2,429 |
| Intuitive Surgical | 5 | $2,100 |
| Axonics, Inc. | 35 | $1,469 |
| AbbVie(2 entities) | 14 | $323 |
| Sumitomo Pharma America, Inc. | 10 | $195 |
| Femselect Inc. | 1 | $106 |
| Mayne Pharma Commercial LLC | 4 | $92 |
| Pfizer | 4 | $81 |
| Hologic Sales And Service, LLC | 3 | $71 |
| Organon | 9 | $62 |
| Astellas Pharma US Inc | 3 | $54 |
| Urovant Sciences Inc | 3 | $53 |
| Mission Pharmacal Company | 3 | $46 |
| Exeltis, USA Inc. | 2 | $45 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Kedrion Biopharma, Inc. | 1 | $25 |
| Amgen | 1 | $25 |
| Cepheid | 1 | $24 |
| Bayer | 1 | $22 |
| Myovant Sciences Inc. | 1 | $22 |
| Therapeuticsmd, Inc. | 1 | $20 |
| Duchesnay USA Incorporated | 1 | $19 |
| Heron Therapeutics, Inc. | 1 | $17 |
| Provepharm Inc. | 1 | $16 |
| Organogenesis Inc. | 1 | $16 |
| Coopersurgical, Inc. | 1 | $16 |
| Coloplast | 1 | $16 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$1,500
- SOLYX$1,190
- Axonics r-SNM System$847
- Bulkamid$847
- Da Vinci Surgical System$564
- GENERAL FEMALE SUI$446
- XENFORM$335
- SOLYX BLUE$118
- OBTRYX$114
- EnPlace$106
How this compares
$7,422 in reported general payments places this provider in the 60th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
See all urogynecology and reconstructive pelvic surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 82 | $50,437 |
| MyrbetriqMirabegron | 26 | $13,499 |
| Estradiol | 142 | $6,366 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 136 | $1,447 |
| Estradiol (Twice Weekly)Estradiol | 16 | $1,348 |
| Metronidazole | 11 | $423 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 18 | $297 |
| Clobetasol Propionate | 19 | $176 |
| Ibuprofen | 31 | $116 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 20 | $104 |
| Fluconazole | 19 | $101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $195 | $50,43782 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $13,49926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
Other urogynecology and reconstructive pelvic surgery in Miami
- Laura MartinMiami$13K
- Carlos MedinaMiami$9K
- Sujata YavagalMiami$7K
- Pedro Alvarez SotoMiami$6K
- Alexandra Garcia GlinosMiami$4K
- Nathan KowOrlando$116K
- Amir ShariatiCoconut Creek$106K
- Charbel SalamonOrlando$100K
- Allison WymanTampa$69K
- Nicole SzellLargo$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.